Skip to main content
TipRanks
Go Ultimate75% OFF

Artelo Biosciences (ARTL) AI Stock Analysis

591 Followers
ARTL

Artelo Biosciences

(NASDAQ:ARTL)

Select Model
Rating:41Neutral
Price Target:$1.50â–²(0.00% Upside)
Action:upgraded
Date:11/13/26

The score is driven primarily by weak financial performance (no revenue, multi-year losses, and worsening cash burn), which elevates financing risk. Technicals also weigh on the outlook with price below key moving averages and negative MACD, though near-oversold momentum provides only limited offset. Valuation is constrained by negative earnings (negative P/E), and corporate-event risk is heightened by Nasdaq listing compliance uncertainty.

Positive Factors
Focused clinical pipelineA focused development strategy around lipid-signaling pathways gives Artelo a defined scientific direction and supports concentrated use of its limited resources. If its candidates advance clinically, this platform focus could create opportunities across inflammation, cancer-related anorexia, and related conditions over time.
Negative Factors
Pre-revenue business modelPersistent zero revenue means Artelo currently has no demonstrated commercial top line to fund research, clinical development, or corporate expenses. The company therefore remains dependent on successful product development and eventual commercialization, making the path to sustainable internally generated funding highly uncertain.

Artelo Biosciences (ARTL) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%ARTL-96.67%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$5.86M
Dividend Yield
―
Average Volume (3M)
476.60K
Price to Earnings (P/E)
-0.0
Beta (1Y)
-0.62
Revenue Growth
―
EPS Growth
81.76%
Country
US
Employees
7
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Artelo Biosciences Business Overview & Revenue Model

Company Description

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising...

Artelo Biosciences Financial Statement Overview

Summary

Financials reflect an early-stage, high-risk profile: $0 revenue across all shown periods, recurring sizable net losses (TTM net loss about -$11.3M), and negative/worsening operating and free cash flow (FCF about -$11.8M TTM), indicating an elevated cash-burn and financing need. A key offset is low leverage (about $40K total debt) and positive equity in TTM (~$6.2M), but overall funding sustainability remains the central risk.

Income Statement

12Very Negative

Balance Sheet

48Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Mar 2023Aug 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-10.81M-12.54M-9.83M-9.29M-10.08M-7.44M
Net Income-11.32M-12.88M-9.83M-9.29M-10.08M-7.44M
Balance Sheet
Total Assets6.67M2.80M4.70M13.04M20.42M12.63M
Cash, Cash Equivalents and Short-Term Investments4.44M600.00K2.34M10.43M17.53M10.06M
Total Debt40.00K678.00K104.00K23.00K63.00K95.00K
Total Liabilities439.00K4.07M1.84M1.29M1.02M593.00K
Stockholders Equity6.24M-1.27M2.86M11.75M19.40M12.04M
Cash Flow
Free Cash Flow-11.76M-8.52M-8.35M-8.21M-8.01M-6.14M
Operating Cash Flow-11.76M-8.52M-8.35M-8.21M-8.01M-6.14M
Investing Cash Flow188.00K-62.00K7.77M3.51M2.96M-3.44M
Financing Cash Flow14.26M6.87M112.00K567.00K014.11M

Artelo Biosciences Technical Analysis

Technical Analysis SentimentNegative
Last Price1.50

Price Trends

50DMA3.29Negative
100DMA5.56Negative
200DMA19.11Negative

Market Momentum

MACD-0.41Negative
RSI28.68Positive
STOCH16.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTL, the sentiment is Negative. The current price of 1.50 is below the 20-day moving average (MA) of 2.19, below the 50-day MA of 3.29, and below the 200-day MA of 19.11, indicating a bearish trend. The MACD of -0.41 indicates Negative momentum. The RSI at 28.68 is Positive, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTL.

Artelo Biosciences Risk Analysis

Artelo Biosciences disclosed 56 risk factors in its most recent earnings report. Artelo Biosciences reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Artelo Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ARTL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ENVBENVB47Neutral$6.36M-0.23-163.22%――93.45%
INDPINDP47Neutral$509.96M-0.82-206.82%――87.31%
TOVXTOVX42Neutral$6.61M-0.57-64.99%――95.48%
ARTLARTL41Neutral$1.57M-0.02-272.21%――81.76%
BDRXBDRX40Underperform$1.07M-38.71-42.42%――97.97%

* Healthcare Sector Average

Performance Comparison

-100%0%100%ARTLBDRXTOVXINDPENVBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ARTL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ARTLArtelo Biosciences1.50-44.67-96.75%
BDRXBiodexa Pharmaceuticals Plc2.04-155.16-98.71%
TOVXTheriva Biologics, Inc.0.14-0.07-32.71%
INDPIndaptus Therapeutics, Inc.3.291.5488.00%
ENVBEnveric Biosciences, Inc.1.42-4.43-75.73%

Artelo Biosciences Corporate Events

Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance

Artelo Biosciences Addresses Nasdaq Listing Compliance Uncertainty

Negative
Oct 9, 2026

On July 22, 2026, the SEC approved Nasdaq’s new $5,000,000 market value of listed securities rule, which exposes companies below that threshold, including Artelo Biosciences, to potential delisting unless they regain compliance. The rule was temporar...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026